Profusa (NASDAQ: PFSA), a commercial-stage digital health company, solidified its position in the biochemical monitoring market this week after presenting…
Read More »Healthcare
The last four months proved transformative for Profusa (NASDAQ: PFSA). The company emerged from a whirlwind of activity with a…
Read More »
Digital health company Profusa (NASDAQ: PFSA) recently laid out one of the most ambitious commercial roadmaps the biosensor sector has…
Read More »
Berkeley-based digital health innovator Profusa (NASDAQ: PFSA) just cleared a major hurdle on its path to commercialization. The company announced…
Read More »
Armata Pharmaceuticals (NYSE American: ARMP) surprised Wall Street on Wednesday after its stock rocketed as much as 370% intraday on…
Read More »
Profusa (NASDAQ: PFSA) is advancing on two fronts this month, expanding its European commercialization footprint for its Lumee™ Oxygen platform…
Read More »
Profusa (NASDAQ: PFSA) is extending its footprint in European healthcare with the addition of one of France’s top vascular surgeons…
Read More »
Nvidia (NASDAQ: NVDA) hasn’t just ridden the AI wave; it’s helped shape it, on the chip side and, increasingly, through…
Read More »
Profusa (NASDAQ: PFSA) is quickly building momentum across Europe, adding leading vascular specialists to its clinical network while also preparing…
Read More »
Why Profusa Stands Out in Small-Cap Investing Profusa (NASDAQ: PFSA) is a biotech company that is developing tissue‑integrating biosensors for…
Read More »